Last reviewed 2026-04-22 · How we verify

AXS-12 (Reboxetine)

Reboxetine is a selective norepinephrine reuptake inhibitor (NRI) that increases norepinephrine levels in the brain by blocking its reuptake at the presynaptic neuron.

Reboxetine is a selective norepinephrine reuptake inhibitor (NRI) that increases norepinephrine levels in the brain by blocking its reuptake at the presynaptic neuron. Used for Major depressive disorder, Attention-deficit/hyperactivity disorder (ADHD).

At a glance

Mechanism of action

By inhibiting the norepinephrine transporter, reboxetine prevents the reabsorption of norepinephrine from the synaptic cleft, thereby increasing its concentration and duration of action. This mechanism enhances noradrenergic neurotransmission, which is thought to improve mood, attention, and motivation. Reboxetine has minimal effects on serotonin or dopamine reuptake, distinguishing it from other antidepressants.

Approved indications

• Major depressive disorder
• Attention-deficit/hyperactivity disorder (ADHD)

Common side effects

• Insomnia
• Dry mouth
• Sweating
• Tachycardia
• Urinary retention
• Headache

Key clinical trials

• A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE) (PHASE3)
• A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy (PHASE3)
• Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• AXS-12 (Reboxetine) CI brief — competitive landscape report
• AXS-12 (Reboxetine) updates RSS · CI watch RSS
• Axsome Therapeutics, Inc. portfolio CI